Can i cut sumatriptan in half

Ischemic optic neuropathy, retinal artery occlusion, retinal vein thrombosis, loss of vision. Central nervous system vasculitis, cerebrovascular accident, dysphasia, serotonin syndrome, subarachnoid hemorrhage.

Overdose in animals has been fatal and has been heralded by convulsions, tremor, paralysis, inactivity, ptosis, erythema of the extremities, abnormal respiration, cyanosis, ataxia, mydriasis, salivation, and lacrimation. It is unknown what effect hemodialysis or peritoneal dialysis has on the serum concentrations of sumatriptan. There is also evidence that doses of mg do not provide a greater effect than 50 mg.

The choice of dose should therefore be made on an individual basis, weighing the possible benefit of a higher dose with the potential for a greater risk of adverse events. If the headache returns or the patient has a partial response to the initial dose, the dose may be repeated after 2 hours, not to exceed a total daily dose of mg.

The safety of treating an average of more than 4 headaches in a day period has not been established. Dogs receiving oral sumatriptan developed corneal opacities and defects in the corneal epithelium.

Defects in the corneal epithelium were noted in a week study. Earlier examinations for these toxicities were not conducted and no-effect doses were not established; however, the relative exposure at the lowest dose tested was approximately 5 times the human exposure after a mg oral dose. There is evidence of alterations in corneal appearance on the first day of intranasal dosing to dogs.

This product's prescribing information may have been updated. Please refer to www. Read the leaflet that comes with each refill of your prescription because there may be new information. Ask your healthcare provider for more information or advice. You should take it only if you have a prescription.

They are not used to prevent attacks or reduce the number of attacks you have. If you do have risk factors for heart disease, your healthcare provider should check you for heart disease to see if IMITREX is right for you. Usually, serious problems happened in people with known heart disease. Remember, if you answered YES to any of the above questions, then talk with your healthcare provider about it. Do not take IMITREX Tablets if you are pregnant, think you might be pregnant, are trying to become pregnant, or are not using adequate contraception unless you have talked with your healthcare provider about this.

For adults, the usual dose is a single tablet swallowed whole with water or other liquids. Do not split tablets. If your symptoms of migraine come back or if you have a partial response to the first dose, you can take a second tablet 2 hours after the first tablet, but not sooner. Use caution for activities requiring alertness like driving or using machines.

If you have taken more medicine than has been prescribed for you, contact either your healthcare provider, hospital emergency department, or nearest poison control center right away. Keep your medicine in a safe place where children cannot reach it. It may be harmful to children. Store your medicine away from heat and light. The expiration date of your medicine is printed on the packaging. If your medicine has expired, throw it away.

If your healthcare provider decides to stop your treatment, do not keep any leftover medicine unless your healthcare provider tells you to. The other brands listed are trademarks of their respective owners and are not trademarks of GlaxoSmithKline. The makers of these brands are not affiliated with and do not endorse GlaxoSmithKline or its products. DailyMed will deliver notification of updates and additions to Drug Label information currently shown on this site through its RSS feed.

DailyMed will deliver this notification to your desktop, Web browser, or e-mail depending on the RSS Reader you select to use. Due to inconsistencies between the drug labels on DailyMed and the pill images provided by RxImage , we no longer display the RxImage pill images associated with drug labels.

We anticipate reposting the images once we are able identify and filter out images that do not match the information provided in the drug labels.

View Package Photos. Drug Label Info. Mechanism of Action Sumatriptan is an agonist for a vascular 5-hydroxytryptamine 1 receptor subtype probably a member of the 5-HT 1D family having only a weak affinity for 5-HT 1A , 5-HT 5A , and 5-HT 7 receptors and no significant affinity as measured using standard radioligand binding assays or pharmacological activity at 5-HT 2 , 5-HT 3, or 5-HT 4 receptor subtypes or at alpha 1 -, alpha 2 -, or beta-adrenergic; dopamine 1 ; dopamine 2 ; muscarinic; or benzodiazepine receptors.

Special Populations Renal Impairment The effect of renal impairment on the pharmacokinetics of sumatriptan has not been examined, but little clinical effect would be expected as sumatriptan is largely metabolized to an inactive substance. Hepatic Impairment The liver plays an important role in the presystemic clearance of orally administered sumatriptan. Gender In a study comparing females to males, no pharmacokinetic differences were observed between genders for AUC, C max , T max , and half-life.

Alcohol Alcohol consumed 30 minutes prior to sumatriptan ingestion had no effect on the pharmacokinetics of sumatriptan. Table 1. Premarketing Experience With Sumatriptan Of 6, patients with migraine who participated in premarketing controlled and uncontrolled clinical trials of oral sumatriptan, 2 experienced clinical adverse events shortly after receiving oral sumatriptan that may have reflected coronary vasospasm.

Drug-Associated Cerebrovascular Events and Fatalities Cerebral hemorrhage, subarachnoid hemorrhage, stroke, and other cerebrovascular events have been reported in patients treated with oral or subcutaneous sumatriptan, and some have resulted in fatalities. Other Vasospasm-Related Events Sumatriptan may cause vasospastic reactions other than coronary artery vasospasm.

Increase in Blood Pressure Significant elevation in blood pressure, including hypertensive crisis, has been reported on rare occasions in patients with and without a history of hypertension. Concomitant Drug Use In patients taking MAO-A inhibitors, sumatriptan plasma levels attained after treatment with recommended doses are 7-fold higher following oral administration than those obtained under other conditions.

Binding to Melanin-Containing Tissues In rats treated with a single subcutaneous dose 0. Corneal Opacities Sumatriptan causes corneal opacities and defects in the corneal epithelium in dogs; this raises the possibility that these changes may occur in humans. Ergot-Containing Drugs Ergot-containing drugs have been reported to cause prolonged vasospastic reactions.

Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis In carcinogenicity studies, rats and mice were given sumatriptan by oral gavage rats: weeks or drinking water mice: 78 weeks.

Pregnancy Pregnancy Category C. Embryolethality When given orally or intravenously to pregnant rabbits daily throughout the period of organogenesis, sumatriptan caused embryolethality at doses at or close to those producing maternal toxicity. Nursing Mothers Sumatriptan is excreted in human breast milk following subcutaneous administration.

Geriatric Use The use of sumatriptan in elderly patients is not recommended because elderly patients are more likely to have decreased hepatic function, they are at higher risk for CAD, and blood pressure increases may be more pronounced in the elderly see WARNINGS.

Incidence in Controlled Clinical Trials Table 2 lists adverse events that occurred in placebo-controlled clinical trials in patients who took at least 1 dose of study drug. Table 2. Atypical Sensations Frequent were burning sensation and numbness. Cardiovascular Frequent were palpitations, syncope, decreased blood pressure, and increased blood pressure. Ear, Nose, and Throat Frequent were sinusitis, tinnitus; allergic rhinitis; upper respiratory inflammation; ear, nose, and throat hemorrhage; external otitis; hearing loss; nasal inflammation; and sensitivity to noise.

Endocrine and Metabolic Infrequent was thirst. Eye Rare were disorders of sclera, mydriasis, blindness and low vision, visual disturbances, eye edema and swelling, eye irritation and itching, accommodation disorders, external ocular muscle disorders, eye hemorrhage, eye pain, and keratitis and conjunctivitis. Gastrointestinal Frequent were diarrhea and gastric symptoms. Hematological Disorders Rare was anemia. Musculoskeletal Frequent was myalgia. Neurological Frequent were phonophobia and photophobia.

Respiratory Frequent was dyspnea. Skin Frequent was sweating. Breasts Infrequent was tenderness. Urogenital Infrequent were dysmenorrhea, increased urination, and intermenstrual bleeding.

Miscellaneous Frequent was hypersensitivity. Atypical Sensations Feeling strange, prickling sensation, tingling, and hot sensation. Cardiovascular Abdominal aortic aneurysm, abnormal pulse, flushing, phlebitis, Raynaud syndrome, and various transient ECG changes nonspecific ST or T wave changes, prolongation of PR or QTc intervals, sinus arrhythmia, nonsustained ventricular premature beats, isolated junctional ectopic beats, atrial ectopic beats, delayed activation of the right ventricle.

Chest Symptoms Chest discomfort. Endocrine and Metabolic Dehydration. Eye Vision alterations. Injection Site Reaction. Mouth and Teeth Disorder of mouth and tongue e. Respiratory Influenza and diseases of the lower respiratory tract and lower respiratory tract infection. Skin Skin eruption, herpes, and peeling of the skin. Urogenital Disorder of breasts, endometriosis, and renal calculus. Postmarketing Experience Reports for Subcutaneous or Oral Sumatriptan The following section enumerates potentially important adverse events that have occurred in clinical practice and that have been reported spontaneously to various surveillance systems.

Blood Hemolytic anemia, pancytopenia, thrombocytopenia. Ear, Nose, and Throat Deafness. Eye Ischemic optic neuropathy, retinal artery occlusion, retinal vein thrombosis, loss of vision. Hepatic Elevated liver function tests.

Neurological Central nervous system vasculitis, cerebrovascular accident, dysphasia, serotonin syndrome, subarachnoid hemorrhage. Psychiatry Panic disorder. Respiratory Bronchospasm in patients with and without a history of asthma. Urogenital Acute renal failure. Corneal Opacities Dogs receiving oral sumatriptan developed corneal opacities and defects in the corneal epithelium. All rights reserved. The following wording is contained in a separate leaflet provided for patients.

Talk with your healthcare provider before taking IMITREX Tablets Risk factors for heart disease to tell your healthcare provider: Tell your healthcare provider if you have risk factors for heart disease such as: If you do have risk factors for heart disease, your healthcare provider should check you for heart disease to see if IMITREX is right for you.

Are you pregnant? Do you think you might be pregnant? Are you trying to become pregnant? Are you not using adequate contraception? Are you breastfeeding? Do you have any chest pain, heart disease, shortness of breath, or irregular heartbeats?

Have you had a heart attack? Do you have risk factors for heart disease see list above? Have you had a stroke, a mini-stroke also called a transient ischemic attack or TIA , or Raynaud syndrome? Do you have high blood pressure? Do not use this medicine if you have used an MAO inhibitor in the past 14 days, such as isocarboxazid, linezolid, methylene blue injection, phenelzine, rasagiline, selegiline, or tranylcypromine. Do not use sumatriptan within 24 hours before or after using any other migraine headache medicine.

Sumatriptan is a headache medicine that narrows blood vessels around the brain. Sumatriptan also reduces substances in the body that can trigger headache pain, nausea, sensitivity to light and sound, and other migraine symptoms. Sumatriptan is used to treat migraine headaches in adults. Sumatriptan will only treat a headache. This medicine will not prevent headaches or reduce the number of attacks.

Sumatriptan should not be used to treat a common tension headache or a headache that causes loss of movement on one side of your body. Use this medicine only if your condition has been confirmed by a doctor as migraine headaches. Do not use sumatriptan if you have used an MAO inhibitor in the past 14 days. A dangerous drug interaction could occur. MAO inhibitors include isocarboxazid, linezolid, methylene blue injection, phenelzine, rasagiline, selegiline, tranylcypromine, and others.

Be sure your doctor knows if you also take stimulant medicine, opioid medicine, herbal products, or medicine for depression, mental illness, Parkinson's disease, serious infections, or prevention of nausea and vomiting. These medicines may interact with sumatriptan and cause a serious condition called serotonin syndrome. It is not known whether this medicine will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant. You should not breastfeed within 12 hours after using sumatriptan.

If you use a breast pump during this time, throw out any milk you collect. Do not feed it to your baby. Use sumatriptan as soon as you notice headache symptoms. Follow all directions on your prescription label and read all medication guides or instruction sheets. Use the medicine exactly as directed. You may receive your first dose in a hospital or clinic setting to quickly treat any serious side effects. Read and carefully follow any Instructions for Use provided with your medicine.

Ask your doctor or pharmacist if you do not understand these instructions. Do not take a sumatriptan nosepiece capsule by mouth. It is for use only in the nasal inhaler device provided with this medicine. After using sumatriptan: If your headache does not completely go away, or goes away and comes back, use a second dose if it has been at least 2 hours since your first dose. Never use more than your recommended dose.

Overuse of migraine headache medicine can make headaches worse. Sign up for free, and stay up-to-date on research advancements, health tips and current health topics, like COVID, plus expert advice on managing your health. Error Email field is required. Error Include a valid email address. To provide you with the most relevant and helpful information and to understand which information is beneficial, we may combine your e-mail and website usage information with other information we have about you.

If we combine this information with your PHI, we will treat all of that information as PHI, and will only use or disclose that information as set forth in our notice of privacy practices.

You may opt-out of e-mail communications at any time by clicking on the Unsubscribe link in the e-mail. Our Housecall e-newsletter will keep you up-to-date on the latest health information. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes. Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission. Any use of this site constitutes your agreement to the Terms and Conditions and Privacy Policy linked below.

This site complies with the HONcode standard for trustworthy health information: verify here. This content does not have an English version. This content does not have an Arabic version. See more conditions.